Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/29959
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Demetri, George D | - |
dc.contributor.author | De Braud, Filippo | - |
dc.contributor.author | Drilon, Alexander | - |
dc.contributor.author | Siena, Salvatore | - |
dc.contributor.author | Patel, Manish R | - |
dc.contributor.author | Cho, Byoung Chul | - |
dc.contributor.author | Liu, Stephen V | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Chiu, Chao-Hua | - |
dc.contributor.author | Lin, Jessica J | - |
dc.contributor.author | Goto, Koichi | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Bazhenova, Lyudmila | - |
dc.contributor.author | John, Thomas | - |
dc.contributor.author | Fakih, Marwan | - |
dc.contributor.author | Chawla, Sant P | - |
dc.contributor.author | Dziadziuszko, Rafal | - |
dc.contributor.author | Seto, Takashi | - |
dc.contributor.author | Heinzmann, Sebastian | - |
dc.contributor.author | Pitcher, Bethany | - |
dc.contributor.author | Chen, David | - |
dc.contributor.author | Wilson, Timothy R | - |
dc.contributor.author | Rolfo, Christian | - |
dc.date.accessioned | 2022-06-22T06:41:14Z | - |
dc.date.available | 2022-06-22T06:41:14Z | - |
dc.date.issued | 2022-04-01 | - |
dc.identifier.citation | Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2022; 28(7): 1302-1312 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/29959 | - |
dc.description.abstract | Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This article expands prior reports with additional patients and longer follow-up. Patients with locally advanced/metastatic NTRK fusion-positive solid tumors and ≥12 months' follow-up were included. Primary endpoints were ORR and DoR by blinded independent central review (BICR); secondary endpoints included progression-free survival (PFS), intracranial efficacy, and safety. The safety-evaluable populations included all patients who had received ≥1 entrectinib dose. At clinical cut-off (August 31, 2020), the efficacy-evaluable population comprised 121 adults with 14 tumor types and ≥30 histologies. Median follow-up was 25.8 months; 61.2% of patients had a complete (n = 19) or partial response (n = 55). Median DoR was 20.0 months [95% confidence interval (CI), 13.0-38.2]; median PFS was 13.8 months (95% CI, 10.1-19.9). In 11 patients with BICR-assessed measurable central nervous system (CNS) disease, intracranial ORR was 63.6% (95% CI, 30.8-89.1) and median intracranial DoR was 22.1 (95% CI, 7.4-not estimable) months. The safety profile of entrectinib in adults and pediatric patients was aligned with previous reports. Most treatment-related adverse events (TRAEs) were grade 1/2 and manageable/reversible with dose modifications. TRAE-related discontinuations occurred in 8.3% of patients. With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with NTRK fusion-positive solid tumors. | en |
dc.language.iso | eng | |
dc.title | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical Cancer Research : An Official Journal of the American Association for Cancer Research | en |
dc.identifier.affiliation | Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts.. | en |
dc.identifier.affiliation | Peter MacCallum Cancer Center, Melbourne, Australia.. | en |
dc.identifier.affiliation | Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.. | en |
dc.identifier.affiliation | Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, New York.. | en |
dc.identifier.affiliation | Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.. | en |
dc.identifier.affiliation | Department of Medicine, University of Minnesota, Minneapolis, Minnesota.. | en |
dc.identifier.affiliation | Yonsei Cancer Hospital, Seoul, Republic of Korea.. | en |
dc.identifier.affiliation | Georgetown University, Washington, D.C.. | en |
dc.identifier.affiliation | Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.. | en |
dc.identifier.affiliation | Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.. | en |
dc.identifier.affiliation | Massachusetts General Hospital, Boston, Massachusetts.. | en |
dc.identifier.affiliation | National Cancer Center Hospital East, Kashiwa, Japan.. | en |
dc.identifier.affiliation | University of California San Diego, San Diego, California.. | en |
dc.identifier.affiliation | City of Hope Comprehensive Cancer Center, Duarte, California.. | en |
dc.identifier.affiliation | Sarcoma Oncology Center, Santa Monica, California.. | en |
dc.identifier.affiliation | Department of Oncology and Radiotherapy and Early Clinical Trials Unit, Medical University of Gdansk, Gdansk, Poland.. | en |
dc.identifier.affiliation | National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.. | en |
dc.identifier.affiliation | F. Hoffmann-La Roche Ltd, Basel, Switzerland.. | en |
dc.identifier.affiliation | F. Hoffmann-La Roche Ltd, Mississauga, Canada.. | en |
dc.identifier.affiliation | Genentech Inc., South San Francisco, California.. | en |
dc.identifier.affiliation | Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.. | en |
dc.identifier.affiliation | Olivia Newton-John Cancer Wellness and Research Centre | en |
dc.identifier.affiliation | Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.. | en |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/35144967/ | en |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-3597 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-0045-4809 | en |
dc.identifier.orcid | 0000-0001-6806-9061 | en |
dc.identifier.orcid | 0000-0002-2681-2846 | en |
dc.identifier.orcid | 0000-0003-2752-945X | en |
dc.identifier.orcid | 0000-0002-5562-270X | en |
dc.identifier.orcid | 0000-0002-4852-3914 | en |
dc.identifier.orcid | 0000-0002-5740-9654 | en |
dc.identifier.orcid | 0000-0001-7373-3916 | en |
dc.identifier.orcid | 0000-0002-3023-2510 | en |
dc.identifier.orcid | 0000-0001-8764-4359 | en |
dc.identifier.orcid | 0000-0003-3399-5342 | en |
dc.identifier.orcid | 0000-0002-2960-4364 | en |
dc.identifier.orcid | 0000-0002-2341-974X | en |
dc.identifier.pubmedid | 35144967 | |
local.name.researcher | John, Thomas | |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.